Literature DB >> 23396253

Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma.

Rucksak Rucksaken1, Jarinya Khoontawad, Sittiruk Roytrakul, Porntip Pinlaor, Yusuke Hiraku, Chaisiri Wongkham, Chawalit Pairojkul, Thidarut Boonmars, Somchai Pinlaor.   

Abstract

Proteomic analysis was performed to search for the diagnostic biomarkers of the early stage of cholangiocarcinoma (CCA). For this purpose, CCA was experimentally induced in hamsters by the combination of N-nitrosodimethylamine (NDMA) treatment and Opisthorchis viverrini (OV) infection. Pooled plasma of normal control, NDMA-treated, OV-infected and OV+NDMA (ON) treated group was separated by 1-D PAGE, and the trypsin-digested bands were analyzed with LC-MS/MS. Among 82 overexpressed proteins, the study focused on 26 proteins overexpressed in ON group because CCA development was almost exclusively found in this group. A further selection was made based on the protein overexpression on day 21, the precancerous stage. Orosomucoid 2 (Orm2) was overexpressed in OV and ON groups and kinesin 18A (KIF18A) was overexpressed in the ON group. The overexpression levels were verified by real-time RT-PCR and western blotting in the liver and plasma. The transcription and translation levels of these two candidate molecules increased significantly at 21 days post-treatment before tumor development. Immunohistochemistry revealed KIF18A was expressed in the epithelial cells of newly formed small bile ducts, some inflammatory cells and hepatocytes. These results suggest that Orm2 and KIF18A could be the potential biomarkers for early diagnosis of CCA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23396253     DOI: 10.3233/CBM-130296

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  16 in total

1.  Clinicopathological relevance of kinesin family member 18A expression in invasive breast cancer.

Authors:  Mai Kasahara; Makoto Nagahara; Tsuyoshi Nakagawa; Toshiaki Ishikawa; Takanobu Sato; Hiroyuki Uetake; Kenichi Sugihara
Journal:  Oncol Lett       Date:  2016-07-07       Impact factor: 2.967

Review 2.  Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches.

Authors:  Atit Silsirivanit; Kanlayanee Sawanyawisuth; Gregory J Riggins; Chaisiri Wongkham
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-02-12       Impact factor: 7.027

3.  Elevated expression of KIF18A enhances cell proliferation and predicts poor survival in human clear cell renal carcinoma.

Authors:  Q I Chen; Bin Cao; Ning Nan; Y U Wang; X U Zhai; Youfang Li; Tie Chong
Journal:  Exp Ther Med       Date:  2016-05-11       Impact factor: 2.447

4.  Novel Potential Biomarkers for Opisthorchis viverrini Infection and Associated Cholangiocarcinoma.

Authors:  Nithikoon Aksorn; Sittiruk Roytrakul; Suthathip Kittisenachai; Kawin Leelawat; Pithi Chanvorachote; Supachai Topanurak; Shinjiro Hamano; Usa Lek-Uthai
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

5.  Orosomucoid 2 inhibits tumor metastasis and is upregulated by CCAAT/enhancer binding protein β in hepatocellular carcinomas.

Authors:  Tao Fang; Meiling Cui; Ji Sun; Chao Ge; Fangyu Zhao; Lin Zhang; Hua Tian; Lixing Zhang; Taoyang Chen; Guoping Jiang; Haiyang Xie; Ying Cui; Ming Yao; Hong Li; Jinjun Li
Journal:  Oncotarget       Date:  2015-06-30

6.  Diagnostic and prognostic serum marker of cholangiocarcinoma (Review).

Authors:  Xiaojun Zeng; Hualin Tao
Journal:  Oncol Lett       Date:  2014-11-10       Impact factor: 2.967

7.  Sumoylation of Kif18A plays a role in regulating mitotic progression.

Authors:  Feikun Yang; Yan Chen; Wei Dai
Journal:  BMC Cancer       Date:  2015-03-28       Impact factor: 4.430

8.  High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma.

Authors:  Weijia Liao; Guojin Huang; Yan Liao; Jianjun Yang; Qian Chen; ShengJun Xiao; Junfei Jin; Songqing He; Changming Wang
Journal:  Oncotarget       Date:  2014-11-15

9.  KIF15 promotes pancreatic cancer proliferation via the MEK-ERK signalling pathway.

Authors:  Jie Wang; Xingjun Guo; Chencheng Xie; Jianxin Jiang
Journal:  Br J Cancer       Date:  2017-06-08       Impact factor: 7.640

Review 10.  Mechanisms of Chromosome Congression during Mitosis.

Authors:  Helder Maiato; Ana Margarida Gomes; Filipe Sousa; Marin Barisic
Journal:  Biology (Basel)       Date:  2017-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.